Is a Mass Immunization Program for Pandemic (H1N1) 2009 Good Value for Money? Early Evidence from the Canadian Experience. | Zendy

Beate Sander | Zendy; Chris T. Bauch | Zendy; David N. Fisman | Zendy; R Fowler | Zendy; Jeffrey C. Kwong | Zendy; Allison McGeer | Zendy; Marija Zivkovic Gojovic | Zendy; Murray Krahn | Zendy

Open Access

Is a Mass Immunization Program for Pandemic (H1N1) 2009 Good Value for Money? Early Evidence from the Canadian Experience.

Author(s) -

Beate Sander,

Chris T. Bauch,

David N. Fisman,

R Fowler,

Jeffrey C. Kwong,

Allison McGeer,

Marija Zivkovic Gojovic,

Murray Krahn

Publication year - 2009

Publication title -

plos currents

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.282

H-Index - 49

ISSN - 2157-3999

DOI - 10.1371/currents.rrn1137

Subject(s) - pandemic , immunization , h1n1 pandemic , medicine , immunization program , population , outbreak , covid-19 , environmental health , demography , medical emergency , virology , immunology , disease , pathology , antigen , sociology , infectious disease (medical specialty)

This work contributes informed estimates to the current debate about the pandemic (H1N1) 2009 mass immunization program’s economic merits. We performed a cost-utility analysis of the (H1N1) 2009 mass immunization program in Ontario, Canada’s most populous province. The analysis is based on a simulation model of a pandemic (H1N1) 2009 outbreak, surveillance data, and administrative data. We consider no immunization versus mass immunization reaching 30% of the population. Immunization program costs are expected to be $118 million in Ontario. Our analysis indicates this program will reduce influenza cases by 50%, preventing 35 deaths, and cutting treatment costs in half. A pandemic (H1N1) 2009 immunization program is likely to be highly cost-effective.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research